• 1. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 2. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 3. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 4. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 5. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526

Research Brief on 3-Amino-2-bromopyridine-4-acetonitrile (CAS: 1804877-26-6): Recent Advances and Applications in Chemical Biology and Pharmaceutical Research

3-Amino-2-bromopyridine-4-acetonitrile (CAS: 1804877-26-6) is a heterocyclic compound that has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This compound serves as a key intermediate in the synthesis of various biologically active molecules, including kinase inhibitors, antimicrobial agents, and anticancer drugs. Recent studies have highlighted its potential in drug discovery and development, particularly in the design of targeted therapies for complex diseases.

A 2023 study published in the Journal of Medicinal Chemistry explored the use of 3-Amino-2-bromopyridine-4-acetonitrile as a building block for the synthesis of novel Bruton's tyrosine kinase (BTK) inhibitors. The researchers demonstrated that derivatives of this compound exhibited potent inhibitory activity against BTK, a key target in the treatment of B-cell malignancies. The study also revealed that the bromo and cyano functional groups in the molecule play a critical role in enhancing binding affinity and selectivity.

In another recent investigation, scientists utilized 3-Amino-2-bromopyridine-4-acetonitrile to develop a series of antimicrobial agents with broad-spectrum activity. The study, published in Bioorganic & Medicinal Chemistry Letters, reported that the compound's unique structural features enabled the synthesis of derivatives with improved pharmacokinetic properties and reduced toxicity. These findings underscore the compound's potential in addressing the growing challenge of antibiotic resistance.

Further research has focused on the application of 3-Amino-2-bromopyridine-4-acetonitrile in the development of fluorescent probes for biological imaging. A 2024 study in Chemical Communications described the synthesis of a novel probe based on this compound, which exhibited high selectivity for reactive oxygen species (ROS) in cellular environments. This advancement opens new avenues for real-time monitoring of oxidative stress in disease models.

The synthetic versatility of 3-Amino-2-bromopyridine-4-acetonitrile has also been exploited in the design of covalent inhibitors. Recent work published in ACS Chemical Biology demonstrated the compound's utility in creating targeted covalent modifiers for cysteine residues in proteins. This approach has shown promise in the development of therapies for diseases driven by aberrant protein activity.

Despite these advancements, challenges remain in optimizing the physicochemical properties of derivatives based on 3-Amino-2-bromopyridine-4-acetonitrile. Current research efforts are focused on improving solubility and metabolic stability while maintaining target specificity. Computational modeling and structure-activity relationship studies are being employed to guide these optimization efforts.

In conclusion, 3-Amino-2-bromopyridine-4-acetonitrile (CAS: 1804877-26-6) continues to be a valuable scaffold in medicinal chemistry, with recent studies expanding its applications across multiple therapeutic areas. Its unique chemical properties and synthetic accessibility make it an important tool for researchers developing next-generation pharmaceuticals. Future research directions may include exploring its potential in combination therapies and investigating novel synthetic routes to further diversify its derivative library.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)